Taurochenodesoxycholic acid
|
Basic information |
| Metabolite name | Taurochenodesoxycholic acid |
 | HMDB0000951 |
 |
C05465 |
 |
387316 |
| Synonyms | Chenodeoxycholyltaurine; |
| No. of studies | 18 |
|
Basic information |
| Metabolite name | Taurochenodesoxycholic acid |
| HMDB0000951 |
|
C05465 |
|
387316 |
| Synonyms | Chenodeoxycholyltaurine; |
| No. of studies | 18 |
|
Relationship between Taurochenodesoxycholic acid and depression (count: 18) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M061 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M081 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Up |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M1053 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M1053 | Type2 | CUMS + quercetin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M148 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Up |
| Study M148 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | Wistar rat | Up |
| Study M148 | Type2 | CUMS + CSGS group vs. CUMS group | Liver | Wistar rat | Up |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Up |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type2 | CUMS + low dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M604 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M604 | Type2 | CUMS + PBR group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M608 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M608 | Type2 | CUMS + Poria cocos group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M774 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Up |
| Study M847 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M867 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M867 | Type2 | CUMS + Baihe-Dihuang Tang group vs. CUMS group | Plasma | Sprague-Dawley rat | Unknown |
| Study M907 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |